RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets
- 1College of Bioinformatics Science and Technology, Harbin Medical University , 157 Baojian Road, Harbin 150081 ,
Abstract
RNAactDrug 2.0 (available at https://bio-bigdata.hrbmu.edu.cn/RNAactDrug or https://bio-datamining.hrbmu.edu.cn/RNAactDrug) is an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. We have updated the RNAactDrug 2.0 database with significantly expanded data and improved features, including (i) ∼30 000 drugs, 38 908 RNA molecules, and 22 800 375 drug–RNA associations from large-scale pharmacogenomic databases, covering four molecular layers: expression, copy number variation (CNV), mutation, and methylation; (ii) 11 099 cases from The Cancer Genome Atlas across 33 cancer types are integrated to support clinical and pan-cancer analyses of drug sensitivity-associated RNA features; (iii) ∼3.8 million cells from >200 single-cell RNA sequencing datasets, spanning 34 cancer types and 38 tissues, enable analysis of cell type-specific patterns and intratumoral heterogeneity; (iv) 26 440 enhancers and 788 444 drug-enhancer associations, combined with potential target prediction, provide an exploratory epigenetic regulatory dimension; (v) enhanced search and browsing functionalities, together with seven tools for functional annotation, pan-cancer analysis, tumor microenvironment profiling, single-cell trajectory and CNV analysis, and enhancer-related analyses. In summary, RNAactDrug 2.0 is a crucial resource for the multi-omics dissection of drug sensitivity-associated molecules, providing important support for the discovery of drug resistance biomarkers and the advancement of personalized therapeutic strategies.
Related
- Exploring molecular interactions between yeast topoisomerase I and RNA polymerase III subunit, Rpc82 using an in-silico approach
- Exploring the potential targets and possible mechanisms of Shenqi Fuzheng Injection in the treatment of cancer-associated muscle wasting based on network pharmacology
- Molecular Dynamics Simulations Reveal a Broadly Open Solution Ensemble for the DNA Holliday Junction: Mg2+ Crossover Bridging and Weak Force-Field Sensitivity
- Fully Automated System for Exploring Molecular Dynamics Trajectories
- AI-generated language remains systematically distinguishable from human communication.
BibTeX
@article{li2026rnaactdrug,
title = {{RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets}},
author = {Feng Li and Liying Pei and Jiangtao Xing and Anhui Kang and Zhe Chen and Wensong Liu and Siyao Lu and Longqi Xu and Xinyi Wang and Chunlong Zhang and Yanjun Xu},
journal = {Nucleic Acids Research},
year = {2026},
month = nov,
doi = {10.1093/nar/gkag1117},
url = {https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkag1117/9006193},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets
AU - Feng Li
AU - Liying Pei
AU - Jiangtao Xing
AU - Anhui Kang
AU - Zhe Chen
AU - Wensong Liu
AU - Siyao Lu
AU - Longqi Xu
AU - Xinyi Wang
AU - Chunlong Zhang
AU - Yanjun Xu
PY - 2026
DA - 2026/11/02
JO - Nucleic Acids Research
DO - 10.1093/nar/gkag1117
UR - https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkag1117/9006193
AB - RNAactDrug 2.0 (available at https://bio-bigdata.hrbmu.edu.cn/RNAactDrug or https://bio-datamining.hrbmu.edu.cn/RNAactDrug) is an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. We have updated the RNAactDrug 2.0 database with significantly expanded data and improved features, including (i) ∼30 000 drugs, 38 908 RNA molecules, and 22 800 375 drug–RNA associations from large-scale pharmacogenomic databases, covering four molecular layers: expression, copy number variation (CNV), mutation, and methylation; (ii) 11 099 cases from The Cancer Genome Atlas across 33 cancer types are integrated to support clinical and pan-cancer analyses of drug sensitivity-associated RNA features; (iii) ∼3.8 million cells from >200 single-cell RNA sequencing datasets, spanning 34 cancer types and 38 tissues, enable analysis of cell type-specific patterns and intratumoral heterogeneity; (iv) 26 440 enhancers and 788 444 drug-enhancer associations, combined with potential target prediction, provide an exploratory epigenetic regulatory dimension; (v) enhanced search and browsing functionalities, together with seven tools for functional annotation, pan-cancer analysis, tumor microenvironment profiling, single-cell trajectory and CNV analysis, and enhancer-related analyses. In summary, RNAactDrug 2.0 is a crucial resource for the multi-omics dissection of drug sensitivity-associated molecules, providing important support for the discovery of drug resistance biomarkers and the advancement of personalized therapeutic strategies.
SN - 0305-1048
SN - 1362-4962
ER -